Related Experiment Video
Updated: Apr 7, 2026
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
69.4K
Alloferon Alleviates Dextran Sulfate Sodium-induced Colitis
Hyemin Kim1, Jong Pil Im2, Joo Sung Kim2
1Department of Anatomy, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul 110-799, Korea.
Immune Network
|July 4, 2015
Summary
Alloferon, an insect-derived peptide, demonstrates significant anti-inflammatory effects by reducing disease severity in a mouse model of inflammatory bowel disease (IBD). This novel immune regulator effectively alleviates colitis symptoms and gut inflammation.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Gut immune dysregulation contributes to inflammatory bowel disease (IBD) pathogenesis.
- Current IBD treatments lack sufficient efficacy, necessitating novel therapeutic strategies.
- Alloferon, an insect-derived peptide, exhibits immunomodulatory and anti-inflammatory properties.
Purpose of the Study:
- To investigate the therapeutic potential of alloferon in dextran sulfate sodium (DSS)-induced colitis, a model of IBD.
- To evaluate alloferon's effects on disease activity, colonic inflammation, and key inflammatory mediators.
Main Methods:
- Colitis was induced in mice using DSS administration.
- Alloferon was administered therapeutically after colitis onset.
- Disease activity index (DAI), colon morphology, and plasma cytokine levels (IL-6) were assessed.
- In vitro studies examined alloferon's effect on TNF-α-induced inflammatory pathways in colon cancer cells.
Main Results:
- Alloferon treatment significantly reduced the disease activity index (DAI) and colon contraction in DSS-induced colitis.
- Histological analysis revealed decreased edema, epithelial erosion, and immune cell infiltration in alloferon-treated mice.
- Alloferon administration led to a reduction in plasma IL-6 levels.
- In vitro, alloferon inhibited TNF-α-induced degradation and phosphorylation of IκB in colon cancer cells.
Conclusions:
- Alloferon exhibits potent anti-inflammatory effects and effectively attenuates DSS-induced colitis in a preclinical model.
- The findings suggest alloferon's potential as a novel therapeutic agent for inflammatory bowel disease.
- Further research is warranted to elucidate the precise mechanisms of action and clinical applicability of alloferon.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
698
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
01:29Drugs for Treatment of Ulcerative Colitis in IBD
654
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
654
01:30Inhibitors of Viral Protein Synthesis
32
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
01:29Inflammatory Bowel Disease IV: Pharmacological Management
967
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
967
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
657
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
657
01:17Drugs for Treatment of Diarrhea-Predominant IBS
903
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
903